MIRA — MIRA PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1904286 ·
Last close
$0.64
Market Cap
$26.89M
52W High
$1.69
52W Low
$0.51
ADV30
132,121
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -1,412,028 -1,422,732 7,267,384 2,504,631 426,176
Jun 2026 0 — -1,156,119 -1,208,534 8,203,140 3,609,442 40,823
Mar 2026 0 — -1,103,479 -1,150,152 9,463,736 4,815,031 114,761
Dec 2025 0 — -5,824,827 -5,983,321 11,093,605 6,346,921 702,068

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,638,863
Investing CF
—
Financing CF
$7,517,830
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.33
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-41,938,892
Inventory
—
Receivables
—
ST Investments
$4,503,973
EBIT TTM
$-9,401,410
Pretax Income TTM
$-9,479,680
Interest Exp TTM
—
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -10,493,112 -10,442,485 11,093,605 702,068 10,391,537 -4,661,669
Dec 2024 0 -8,018,328 -7,852,659 2,923,099 723,349 2,199,750 -5,560,606
Dec 2023 0 -8,526,049 -11,982,343 4,932,443 558,097 4,374,346 -4,532,403
Dec 2022 0 -7,047,940 -7,058,190 858,074 1,454,306 -596,232 -5,604,759

TTM Snapshot

Revenues TTM
—
NetIncome TTM
$-9,479,680
OpCashFlow TTM
—
Assets (Latest)
$8,203,140
Forward EPS
$-0.41

Peers — same industry

TickerNameMarket CapLastDaily %
MCUJF MEDICURE INC $27.45M $2.63 —
RMTI ROCKWELL MEDICAL, INC. $26.25M $6.61 —
BHST BIOHARVEST SCIENCES INC. $27.65M $1.22 —
ACET Adicet Bio, Inc. $26.03M $2.78 —
BETRF BetterLife Pharma Inc. $25.64M $0.15 —

News headlines (Yahoo Finance, 1h cache)

MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain
2026-11-17 13:00 · Yahoo
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
2026-10-29 12:00 · Yahoo
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
2026-10-22 12:00 · Yahoo
Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
2026-09-01 12:04 · Yahoo
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
2026-09-01 12:00 · Yahoo
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
2026-07-30 12:00 · Yahoo
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
2026-07-06 13:00 · Yahoo
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
2026-06-25 12:15 · Yahoo
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
2026-06-17 12:00 · Yahoo
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
2026-06-04 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.